• 한국전산구조공학회논문집
• /
• 제32권6호
• /
• pp.391-399
• /
• 2019

본 논문에서는 해석결과를 보정하여 고층 건축물의 기둥축소 예측값과 실제값 간의 오차를 최소화하기 위한 해석보정법이 제안되었다. 이를 위하여 41층 규모의 철근 콘크리트 건물에 대한 시공단계해석이 수행되었으며, 해석결과는 기둥과 코어로 나뉘어 네 가지의 가정된 계측결과들과 비교되었다. 해석보정은 기둥에서는 오차 한계를 넘어서는 시공단계에서 코어에서는 모든 시공단계에 적용되었으며, 해석이 보정된 이후에도 지속적으로 오차가 발생하므로 해석보정이 자주 수행될수록 오차는 감소하였다. 이러한 과정을 통하여 제안된 해석보정 방법을 적용함으로써 장기적인 축소값이 실제값과 유사하게 예측될 수 있음을 확인하였다.

• 한국미생물·생명공학회지
• /
• 제46권2호
• /
• pp.162-170
• /
• 2018

Non-typhoidal Salmonella is one of the main pathogens causing food-borne illness in humans, with up to 20% of cases resulting from consumption of pork products. Over the gastroenteritis signs, multidrug resistant Salmonella has arisen. In this study, pan-susceptible phenotypic strains of Salmonella enterica serotype Weltevreden recovered from pig production chain in Chiang Mai, Thailand during 2012-2014 were chosen for analysis. The aim of this study was to use whole genome sequencing (WGS) data with an emphasis on antimicrobial resistance gene investigation to assess their pathogenic potential and genetic diversity determination based on whole genome Multilocus Sequence Typing (wgMLST) to expand epidemiological knowledge and to provide additional guidance for disease control. Analyis using ResFinder 3.0 for WGS database tracing found that one of pan-susceptible phenotypic strain carried five classes of resistance genes: aminoglycoside, beta-lactam, phenicol, sulfonamide, and tetracycline associated genes. Twenty four and 36 loci differences were detected by core genome Multilocus Sequence Typing (cgMLST) and pan genome Multilocus Sequence Typing (pgMLST), respectively, in two matching strains (44/13 vs A543057 and A543056 vs 204/13) initially assigned by conventional MLST and Pulsed-field Gel Electrophoresis (PFGE). One hundread percent discriminant ability can be achieved using the wgMLST technique. WGS is currently the ultimate molecular technique for various in-depth studies. As the findings stated above, a new of "gold standard typing method era" for routine works in genome study is being set.

• The Journal of Advanced Prosthodontics
• /
• 제12권5호
• /
• pp.299-306
• /
• 2020

PURPOSE. The aim of this study was to evaluate the accuracy of six recently introduced intraoral scanners (IOSs) for single crown preparations isolated from the complete arch, and to determine the effect of scanning sequence on accuracy. MATERIALS AND METHODS. A complete arch with right and left canine preparations for single crowns was used as a study model. The reference dataset was obtained by scanning the complete arch using a highly accurate industrial scanner (ATOS Core 80, GOM GmbH). Six different IOSs (Trios, iTero, Planmeca Emerald, Cerec Omnicam, Primescan, and Virtuo Vivo) were used to scan the model ten times each. The scans performed with each IOS were divided into two groups, based on whether the scanning sequence started from the right or left quadrant (n=5). The accuracy of digital impression was evaluated using three-dimensional analyzing software (Geomagic Studio 12, 3D Systems). The Kruskal Wallis and Mann- Whitney U statistical tests for trueness analysis and the One-way ANOVA test for precision analysis were performed (α=.05). RESULTS. The trueness and precision values were the lowest with the Primescan (25 and 10 ㎛), followed by Trios (40.5 and 11 ㎛), Omnicam (41.5 ㎛ and 18 ㎛), Virtuo Vivo (52 and 37 ㎛), iTero (70 and 12 ㎛) and Emerald (73.5 and 60 ㎛). Regarding trueness, iTero showed more deviation when scanning started from the right (P=.009). CONCLUSION. The accuracy of digital impressions varied depending on the IOS and scanning sequence used. Primescan had the highest accuracy, while Emerald showed the most deviation in accuracy for single crown preparations.

• Journal of Pharmaceutical Investigation
• /
• 제36권2호
• /
• pp.137-142
• /
• 2006

A bioequivalence of Daewoong $Alendronate^{TM}$ (Daewoong Pharmaceutical Co., Ltd., Korea) and $Fosamax^{TM}$ tablets (MSD Korea) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). A single 70 mg dose of sodium alendronate of each medicine was administered orally to 56 healthy male volunteers. This study was performed in a $2\;{\time}\;2$ crossover design. Concentrations of alendronate in the urine were monitored by a high-performance liquid chromatography (HPLC). $A_{et}$ (cumulative urinary excreted amount from time 0 to last sampling interval) was calculated by the accumulation of the urinary excreted alendronate. $U_{max}$ (maximum urinary excretion rate) and $T_{max}$ (time to reach $U_{max}$) were compiled from the urinary excretion rate - time data. Analysis of variance was performed using logarithmically transformed $A_{et}$ and $U_{max}$. No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the $A_{et}$ and $U_{max}$ for Daewoong $Alendronate^{TM}/Fosamax^{TM}$ were 0.89-1.12 and 0.82-1.02, respectively. This study demonstrated the bioequivalence of Daewoong $Alendronate^{TM}$ and $Fosamax^{TM}$ with respect to the rate and extent of absorption.

• 한국전자파학회논문지
• /
• 제18권2호
• /
• pp.213-218
• /
• 2007

본 논문에서는 CMOS 0.18 ${\mu}m$ 공정을 이용하여 DS-CDMA UWB용 고주파 VCO를 설계하고 제작하였다. 위상 잡음 특성을 좋게 하기 위해서 PMOS, NMOS 소자를 대칭으로 구성한 complementary cross-coupled LC 발진기 구조로 설계하였고, varactor를 이용하여 주파수를 조정하였다. 또한 전류원의 1/f 잡음 신호를 줄이기 위해 저항을 이용하여 전류원을 구성하였다. 스펙트림 분석기를 이용한 측정을 위해 칩 내부에 고속 동작을 위한 인버터 버퍼를 추가로 설계하였다. 제작한 VCO의 core size는 $340{\mu}m{\times}535{\mu}m$이고, 측정한 VCO의 위상 잡음은 1-MHz offset에서 -107 dBc/Hz의 특성을 나타내고, 주파수 조정 범위는 $7.09{\sim}7.52$ GHz의 특성을 보인다 Harmonic suppression은 32 dB, VCO core의 전류 소모는 1.8 V 공급 전압에서 2 mA의 저전력 소모를 나타내도록 설계하였다.

• Journal of Pharmaceutical Investigation
• /
• 제34권4호
• /
• pp.311-317
• /
• 2004

A bioequivalence study of $Gomcillin^{TM}$ capsules (DAEWOONG Pharmaceutical Co., Korea) to $Famoxin^{TM}$ capsules (Dong Wha Pharm. Ind. Co., Korea) was conducted according to the guideline of Korea Food and Drug Administration (KFDA). Twenty four healthy male Korean volunteers received each medicine at the amoxicillin dose of 500 mg in a $2{\times}2$ crossover study. There was a one-week wash out period between the doses. Plasma concentrations of amoxicillin were monitored by a high-performance liquid chromatography for over a period of 8 hours after the administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 8 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Gomcillin^{TM}/Famoxin^{TM}$ were $log0.91\;{\sim}\;log1.03$ and $;log0.93\;{\sim}\;log1.10$, respectively. These values were within the acceptable bioequivalence intervals of $log0.80\;{\sim}\;log1.25$. Thus, our study demonstrated the bioequivalence of $Gomcillin^{TM}$ and $Famoxin^{TM}$ with respect to the rate and extent of absorption.

• Journal of Pharmaceutical Investigation
• /
• 제34권5호
• /
• pp.413-418
• /
• 2004

A bioequivalence of $Melax^{TM}$ capsules (Chong Kun Dang Pharm., Korea) and $Mobic^{TM}$ capsules (Boehringer Ingelheim Korea) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). Single 15 mg dose of meloxicam of each medicine was administered orally to 24 healthy male volunteers. This study was performed in a $2\;{\times}\;2$ crossover design. Concentrations of meloxicam in human plasma were monitored by a high-performance liquid chromatography. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 72 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was performed using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Melax^{TM}/Mobic^{TM}$ were 0.95 - 1.04 and 0.98 - 1.14, respectively. This study demonstrated a bioequivalence of $Melax^{TM}$ and $Mobic^{TM}$ with respect to the rate and extent of absorption.

• Journal of Pharmaceutical Investigation
• /
• 제37권4호
• /
• pp.255-261
• /
• 2007

A bioequivalence study of $Nimegen^{TM}$ soft capsule (Medica Korea Pharma. Co., Ltd.) to $RoAccutane^{(R)}$ soft capsule (Roche Korea Ind. Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Thirty healthy male Korean volunteers received each medicine at the isotretinoin dose of 60 mg in a $2{\times}2$ crossover study. There was one week wash-out period between the doses. Plasma concentrations of isotretinoin were monitored by a high performance liquid chromatography (HPLC) for over a period of 48 hours after drug administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 48 hr) was calculated by the linear trapezoidal rule method. $C_{MAX}$ (maximum plasma drug concentration) and $T_{MAX}$ (time to reach $C_{MAX}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t\;and\;C_{MAX}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{MAX}$ ratio for $Nimegen^{TM}/RoAccutane^{(R)}$ were $log0.860{\sim}log0.98\;and\;log0.85{\sim}log1.00$, respectively. These values were within the acceptable bioequivalence intervals of $log0.80{\sim}log1.25$. Thus, our study demonstrated the bioequivalence of $Nimegen^{TM}\;and\;RoAccutane^{(R)}$ with respect to the rate and extent of absorption.

• Journal of Pharmaceutical Investigation
• /
• 제34권3호
• /
• pp.209-214
• /
• 2004

A bioequivalence study of $Roxithrin^{TM}$ tablet (Kukje Pharma. Ind. Co., Ltd.) to $Rulid^{TM}$ tablet (Han Dok Pharma. Ind. Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty four healthy male Korean volunteers received each medicine at the roxithromycin dose of 300 mg in a $2{\times}2$ crossover study. There was a one-week wash-out period between the doses. Plasma concentrations of roxithromycin were monitored by a high-performance liquid chromatography for over a period of 36 hours after drug administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 36 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the cross-over design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Roxithrin^{TM}/Rulid^{TM}$ were 1.00 - 1.13 and 0.98 - 1.10, respectively. These values were within the acceptable bioequivalence intervals of 0.80 - 1.25. Thus, our study demonstrated the bioequivalence of $Roxithrin^{TM}$ and $Rulid^{TM}$ with respect to the rate and extent of absorption.

• Journal of Pharmaceutical Investigation
• /
• 제34권4호
• /
• pp.319-325
• /
• 2004

A bioequivalence of $Etodol^{TM}$ tablets (Yuhan corporation) and $Kuhnillodine^{TM}$ tablets (Kuhnil Pharm. Co., Ltd.) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). Single 200 mg dose of etodolac of each medicine was administered orally to 24 healthy male volunteers. This study was performed in a $2{\times}2$ crossover design. Concentrations of etodolac in human plasma were monitored by a high-performance liquid chromatography. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 24 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was performed using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Etodol^{TM}/Kuhnillodine^{TM}$ were 1.01-1.10 and 0.87-1.06, respectively. This study demonstrated a bioequivalence of $Etodol^{TM}$ and $Kuhnillodine^{TM}$ with respect to the rate and extent of absorption.